Zacks Investment Research downgraded shares of TORNIER NV (TRNX) from OUTPERFORM to NEUTRAL on May 23, 2013, with a target price of $20.00.
Tornier N.V. operates as a medical device company offering products that treat orthopaedic conditions of the shoulder, elbow, wrist, hand, ankle and foot. The Company's products are organized in four major categories: upper extremity joints and trauma, lower extremity joints and trauma, sports medicine and orthobiologics, and large joints and other. The upper extremity products include joint replacement and bone fixation devices for the shoulder, hand, wrist and elbow lower extremity products include joint replacement and bone fixation devices for the foot and ankle sports medicine and orthobiologics product category includes products used across several anatomic sites to mechanically repair tissue-to-tissue or tissue-to-bone injuries and large joints and other products include hip and knee joint replacement implants and ancillary products. Tornier N.V. is based in Amsterdam, The Netherlands.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on TORNIER NV (TRNX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment